Abstract 98P
Background
We investigate whether the continuation of adjuvant treatment and clinical course of adjuvant treatment would be affected by the development of postoperative complications in the patients who underwent curative resection for colon cancer in a pooled analysis of two large phase III studies performed in Japan.
Methods
The study examined the patients who enrolled in 1303, phase III comparing the efficacy of 6 months and 12 months of capecitabine as adjuvant chemotherapy for stage III colon cancer patients and in 882, a phase III to confirm tolerability oxaliplatin, fluorouracil, and l-leucovorin in Japanese stage II/III colon cancer patients. In this study, POCs were defined as the following major surgical complication; Anastomotic leakage, Pneumonia, Bowel obstruction/ileus, Surgical site infection, Postoperative bleeding, Urinary tract infection, and Fistula. The patients were classified as those with POCs (C group) and those without POCs (NC group).
Results
2095 patients were examined in the present study. POCs were observed in 169 patients (8.1%). The overall survival rates at five-year after surgery was 75.3% in the C-group and 86.5% in NC-group, respectively (p=0.0017). Hazard ratio of POCs for OS was 1.77 (95% confidence interval, 1.23 to 2.54; p=0.0017). Time to adjuvant treatment failure (TTF) of adjuvant chemotherapy was almost similar; 6-months TTF was 68.6% in C-group and 67.1% in NC-group. Dose reduction rate of adjuvant chemotherapy and adjuvant treatment suspension rate were also similar between C-group and NC-group (45.0% vs 48.7%, p=0.3520 and 52.7% vs 55.0%, p=0.5522, respectively).
Conclusions
POCs were associated with the poor prognosis, while the POCs did not affect the intensity of adjuvant chemotherapy. These results suggested that the POCs itself have negative survival impact.
Clinical trial identification
Editorial acknowledgement
This study was supported, in part, by the non-profit organization Epidemiological & Clinical Research Information Network (ECRIN).
Legal entity responsible for the study
Japanese Foundation for Multidisciplinary Treatment of Cancer.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract